Literature DB >> 9697558

Development of a health education programme for elderly with age-related macular degeneration: a focus group study.

S Dahlin-Ivanoff1, K I Klepp, J Sjöstrand.   

Abstract

Age-related macular degeneration is a serious public health problem, and in most cases no cure exists. One available intervention is low vision rehabilitation, and there is a lack of programmes for the elderly. The purpose of this paper is to present the results of an evaluation of a group-based health education programme. This programme comprised six to eight 2-3 hour meetings, once a week, for persons with age-related macular degeneration. Each group consisted of four to six participants. The goal of the programme, which has its roots in the health belief model, was to sustain and restore the participants' performance of their daily activities. The tool used for process evaluation was focus group methodology, and eight focus groups were involved. Forty five persons, whose average age was 80 years, took part in the evaluation. The results indicated that the participants were, on the whole, pleased with the content of the programme. There were, however, some indications that they did not understand all the information provided. Social support, regained hope and meeting others with the same disease were reported as positive aspects of the health education programme. The importance of the group leader's role in guiding this health education programme was emphasised. Furthermore, with regard to the composition of the groups, the participants pointed out that it was important to consider variation in visual acuity, so as to provide different models for comparison, and whether both sexes should participate in all groups. Finally, several suggestions for improving the programme are put forward.

Entities:  

Mesh:

Year:  1998        PMID: 9697558     DOI: 10.1016/s0738-3991(98)00041-x

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  8 in total

Review 1.  Neurovisual rehabilitation: recent developments and future directions.

Authors:  G Kerkhoff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

2.  Patients' knowledge and perspectives on wet age-related macular degeneration and its treatment.

Authors:  Sushma Kandula; Jeffrey C Lamkin; Teresa Albanese; Deepak P Edward
Journal:  Clin Ophthalmol       Date:  2010-05-06

3.  Low vision rehabilitation for better quality of life in visually impaired adults.

Authors:  Ruth Ma van Nispen; Gianni Virgili; Mirke Hoeben; Maaike Langelaan; Jeroen Klevering; Jan Ee Keunen; Ger Hmb van Rens
Journal:  Cochrane Database Syst Rev       Date:  2020-01-27

Review 4.  Quality of life in age-related macular degeneration: a review of the literature.

Authors:  Jan Mitchell; Clare Bradley
Journal:  Health Qual Life Outcomes       Date:  2006-12-21       Impact factor: 3.186

5.  A qualitative investigation into patients' views on visual field testing for glaucoma monitoring.

Authors:  Fiona C Glen; Helen Baker; David P Crabb
Journal:  BMJ Open       Date:  2014-01-10       Impact factor: 2.692

6.  Comparing oculomotor efficiency and visual attention between drivers and non-drivers through the Adult Developmental Eye Movement (ADEM) test: A visual-verbal test.

Authors:  Andrés Gené-Sampedro; Francisco Alonso; Celia Sánchez-Ramos; Sergio A Useche
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

7.  Proposal of a Comprehensive and Multi-Component Approach to Promote Physical Activity among Japanese Office Workers: A Qualitative Focus Group Interview Study.

Authors:  Jihoon Kim; Ryoko Mizushima; Kotaro Nishida; Masahiro Morimoto; Yoshio Nakata
Journal:  Int J Environ Res Public Health       Date:  2022-02-15       Impact factor: 3.390

8.  A qualitative exploration of Australian eyecare professional perspectives on Age-Related Macular Degeneration (AMD) care.

Authors:  Isabelle Jalbert; Dian Rahardjo; Aryati Yashadhana; Gerald Liew; Bamini Gopinath
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.